GE Healthcare Release: DaTSCAN™ (Ioflupane I 123 Injection) SPECT Imaging Demonstrates Impact on the Diagnosis of Patients With Clinically Uncertain Dementia With Lewy Bodies

CHALFONT ST. GILES, England--(BUSINESS WIRE)--GE Healthcare today presented the results of a randomized study analyzing the effect of DaTSCAN™ (Ioflupane I 123 Injection) SPECT imaging in a group of adult patients with a diagnosis of possible dementia with Lewy bodies (DLB). The findings, presented at the 2013 American Academy of Neurology Meeting, reported use of DaTSCAN imaging significantly contributed to a change in diagnostic category and improved physician confidence in diagnosing these patients.1